News & events

Capacity Analysis for Viral Vector Manufacturing: Is There Enough?

LBG’s Dr. Joseph Rininger, Dr. Ashley Fennell, Dr. Lauren Schoukroun-Barnes, Christopher Peterson and Dr. Joshua Speidel recently published a joint article titled, Capacity Analysis for Viral Vector Manufacturing: Is There Enough?.  

The article discusses the increasing demand for viral vectors and whether CDMO capacity is keeping pace with demand. By using a model built to forecast the quantity of viral vectors required to support ongoing and planned clinical trials, the authors suggest that demand will exceed CDMO manufacturing capacity by Q1 2020. 

A must-read if you are in the Viral Vector Manufacturing arena. 

For more information on the findings or how we can support your specific needs email us at info@lathambiopharm.com or set up an appointment with one of our team members here.